Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Molecular Cancer|November 27, 2025
Modeling CIC::DUX4 sarcoma reveals oncogene-mediated MHCI-dependent immune evasionAjay Ram Vachanaram, Erdong Wei, Ana Mitanoska, et al.
JCI Insight|September 18, 2025
Matrix metalloproteinases are hallmark early biomarkers and therapeutic targets in FSHDUsuk Jung, Erdong Wei, Haseeb Ahsan, et al.
Frontiers in Oncology|June 20, 2022
Integration of scRNA-Seq and TCGA RNA-Seq to Analyze the Heterogeneity of HPV+ and HPV- Cervical Cancer Immune Cells and Establish Molecular Risk ModelsErdong Wei, Amin Reisinger, Jiahua Li, et al.
Dermatology (Basel, Switzerland)|October 30, 2022
Comparison of Different Anti-Demodex Strategies: A Systematic Review and Meta-AnalysisJiahua Li, Erdong Wei, Amin Reisinger, et al.
Drug Delivery|April 18, 2017
Polydopamine and peptide decorated doxorubicin-loaded mesoporous silica nanoparticles as a targeted drug delivery system for bladder cancer therapyYi Wei, Li Gao, Lu Wang, et al.
Frontiers in Immunology|March 20, 2023
"From molecular to clinic": The pivotal role of CDC42 in pathophysiology of human papilloma virus related cancers and a correlated sensitivity of afatinibErdong Wei, Jiahua Li, Philipp Anand, et al.
International Journal of Clinical and Experimental Pathology|January 23, 2020
MiR-26a inhibits cell proliferation and induces apoptosis in human bladder cancer through regulating EZH2 bioactivityBaotong Zhou, Erdong Wei, Hailin Shi, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 1, 2018
Anti-proliferative benefit of curcumol on human bladder cancer cells via inactivating EZH2 effectorLi Zhou, Erdong Wei, Baotong Zhou, et al.
Molecular Cancer|October 4, 2024
Pharmacological targeting of P300/CBP reveals EWS::FLI1-mediated senescence evasion in Ewing sarcomaErdong Wei, Ana Mitanoska, Quinn O'Brien, et al.
Pageof 1